The EHMT2 Knockout AGS Polyclonal Cells represent a ready-to-use, CRISPR/Cas9-edited polyclonal knockout cell population in which the gene encoding euchromatic histone-lysine N-methyltransferase 2 (EHMT2, also known as G9a) has been disrupted. This product delivers a heterogeneous ensemble of edited AGS cells generated without single-cell cloning, enabling immediate functional studies of EHMT2-dependent epigenetic regulation. The knockout population is produced by CRISPR/Cas9-mediated gene disruption, creating a loss-of-function model that circumvents the need for clonal isolation while maintaining the inherent biological variability of a polyclonal pool. Researchers benefit from a time-efficient and physiologically relevant tool for dissecting EHMT2 biology in a human gastric adenocarcinoma context.
The AGS host cell line is a widely utilized human gastric adenocarcinoma epithelial model originally derived from the metastatic peritoneal effusion of a female patient with gastric carcinoma. These adherent cells exhibit epithelial morphology and retain key molecular features of gastric cancer, including aberrant signaling through the Wnt/??-catenin and TGF-?? pathways. AGS cells are extensively employed in oncology research, particularly for studying tumor progression, invasion, and drug response, making them an ideal chassis for interrogating the tumorigenic functions of EHMT2. Their robust growth characteristics and ease of genetic manipulation facilitate high-throughput functional genomics and chemical screening applications.
EHMT2 is a histone methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1 and H3K9me2), leading to chromatin compaction and transcriptional repression. It functions as a core component of multi-protein repressor complexes, interacting directly with EHMT1, DNMT1, UHRF1, HP1, and CBX1 to maintain heterochromatic states. EHMT2 activity is regulated by upstream signals including HIF1A, E2F1, MYC, and MEK/ERK signaling, as well as by miR-217-mediated post-transcriptional control. Downstream, EHMT2 represses transcription of key tumor suppressor genes such as CDKN1A (p21), PTEN, CDH1 (E-cadherin), and p53, while also modulating the expression of DNMT1. Through these interactions, EHMT2 integrates environmental and developmental cues to control cell cycle progression, apoptosis, and cellular differentiation.
In AGS gastric cancer cells, EHMT2 is frequently upregulated, where it silences tumor suppressor loci to promote unchecked proliferation and survival. Disruption of EHMT2 in this model relieves H3K9me2-dependent repression, leading to re-expression of genes like p21 and PTEN, and consequent suppression of cell growth, enhanced apoptosis, and reduced invasive capacity. The polyclonal nature of the knockout population recapitulates the heterogeneous response to EHMT2 loss observed in patient tumors, providing a more disease-relevant platform than clonal lines. This model therefore serves as a powerful system to explore how epigenetic dysregulation drives gastric adenocarcinoma and to evaluate therapeutic strategies aimed at restoring normal gene expression patterns.
This EHMT2 knockout AGS cell population supports a broad range of downstream applications in epigenetic cancer research. Typical assays include ChIP-qPCR to directly quantify H3K9me2 enrichment at specific gene promoters, western blotting to assess global H3K9me2 changes and EHMT2 expression, and RNA-seq to profile transcriptome-wide alterations upon knockout. Functional readouts such as MTT or CCK8 cell viability assays, Annexin V/PI apoptosis assays, colony formation assays, and Transwell migration and invasion assays are readily performed. RT-qPCR can be used to validate derepression of tumor suppressors including p21, PTEN, and E-cadherin. The cells are also suited for anti-cancer drug screening, particularly for inhibitors targeting histone methylation or chromatin remodeling. For additional information or custom inquiries, please contact Ascent Research.
